

Who might benefit from chemotherapy delivery via TAMP?

Candidates for TAMP include patients who have experienced limited success or difficulty tolerating the side effects associated with intravenous (IV) chemotherapy. Doctors review your medical history, imaging, and overall health to determine if TAMP could be an option for you.

How does TAMP compare to conventional IV chemotherapy?

With IV chemotherapy, the drug travels through your bloodstream, affecting both cancerous and healthy cells, which can lead to side effects.^{1,2} TAMP delivers targeted chemotherapy directly near the tumor. By focusing treatment where it's needed most, TAMP limits how much of the drug reaches the rest of the body, which may help reduce side effects.^{3,4}

What are the potential benefits of TAMP?

With TAMP, chemotherapy is delivered directly near the tumor, so less of the drug spreads through the rest of the body. This targeted approach may be easier to tolerate than IV chemotherapy and could reduce common side effects. TAMP may also provide an option for tumors that are hard to reach or have limited blood supply.^{3,4}



Visit RenovoCath.com

MKT-2138 Rev A

RENOVO | RX



RENOVO | RX

Frequently Asked Questions

Trans-Arterial Micro-Perfusion (TAMP™)
Targeted Drug-Delivery Platform




What is TAMP?

Trans-Arterial Micro-Perfusion (TAMP) is a drug-delivery platform that provides targeted delivery of chemotherapy directly near the tumor, helping concentrate the chemotherapy drug where it's needed most while limiting exposure to the rest of the body.^{3,4}

Is TAMP FDA-cleared?

The catheter used in the TAMP delivery platform, RenovoCath[®]*, has been FDA-cleared since 2014, meaning it has been reviewed by the U.S. Food and Drug Administration and cleared for use in patients. It is not considered an experimental medical device.⁶



Who performs the procedure?

TAMP is performed by interventional radiologists, doctors specializing in minimally invasive, image-guided treatments, who work with your oncology team to determine if TAMP is right for you.

What can patients expect during the procedure?

The procedure usually takes on average 90 minutes, and most patients go home the same day. You'll receive light sedation to help you relax and stay comfortable. The doctor makes a tiny incision, just a few millimeters, typically in your leg and gently guides a thin catheter (tube) through an artery to the area near the tumor. Once the RenovoCath catheter is in place and the doctor finds the tumor, two small balloons on the catheter are inflated to keep the chemotherapy drug in the treatment area. The chemotherapy drug is then infused between the balloons, creating pressure to push the drug near the tumor. After the procedure, you may feel mild discomfort at the incision site, but most patients return to normal activities in less than a few days.

Do I need to limit my activities after TAMP?

Your doctor may recommend avoiding strenuous exercise or heavy lifting for a few days, especially to allow the catheter incision site in your leg to heal. Your care team will give you specific instructions based on your procedure and overall health.

What follow-up is needed?

After your TAMP procedure, you'll have follow-up visits so your doctor can monitor your health and see how the tumor is responding. This may include imaging scans, like CT or MRI, and blood tests. Based on the results, your doctor will discuss next steps, which could include additional additional TAMP procedures or other treatment options.

Will TAMP interfere with my other cancer treatments?

TAMP is designed to work alongside your other cancer treatments. Your doctors will coordinate when TAMP fits into your care plan with IV chemotherapy and/or radiation, helping your overall treatment be as effective as possible.⁵

Is TAMP safe?

TAMP is a newer approach, but more than 700 procedures have been performed to date with limited side effects reported. Ongoing research continues to help doctors understand its effectiveness and potential use in various cancers.

Is TAMP widely available?

TAMP is being offered at an increasing number of cancer centers, with more locations adopting the procedure all the time. To find a participating physician, you can use the MD locator on our website at www.RenovoCath.com.

Is TAMP covered by insurance?

TAMP is covered by multiple insurance providers. You will need to speak to your insurance provider to verify your individual coverage and benefits.

RENOVO | RX

- 1 <https://www.cancer.org/cancer/managing-cancer/treatmenttypes/chemotherapy.html>
- 2 Maehira, H., et al. (2025). Dynamic changes in tumor blood flow during chemotherapy: Implications in customized treatment for pancreatic cancer. *Oncology Letters*, 30, 579. <https://doi.org/10.3892/ol.2025.15325>.
- 3 Hatoum, H. et al. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2, *The Oncologist*, Volume 29, Issue 8, August 2024, Pages 690–698, <https://doi.org/10.1093/oncolo/oyae178>.
- 4 K. Farsad, et al. Trans-pulmonary artery selective chemotherapy delivery to lung using a double balloon-occlusion catheter. *JVIR*. March 2019; 30 (3).
- 5 <https://www.onclive.com/view/new-jersey-patients-receivingfirst-of-its-kind-catheter-based-pancreatic-cancer-treatment>
- 6 https://www.accessdata.fda.gov/cdrh_docs/pdf21/K212324.pdf*

* **FDA 510(k)-Cleared Intended Use:** *RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath is intended for general intravascular use in the peripheral vasculature in arteries 3mm and larger. The RenovoCath is intended for use in arteries from 3mm in diameter for vessel entry and to occlude vessels ranging between 3mm to 11mm in diameter. The diagnostic and/or therapeutic agents are to be used in accordance with specifications outlined by the respective agent manufacturer.*

Disclaimer: *RenovoRx is evaluating its combination oncology product candidate: intra-arterial gemcitabine via RenovoCath in the ongoing Phase III TIGeR-PaC trial ("IAG"). IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. The study, called TIGeR-PaC ("Intra-Arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC"), is on-going and the combination oncology product candidate (IAG) is not yet cleared or approved by FDA for this use and not yet available for commercial sale.*

